A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties Between NN5401 and NN1250 and Between NN5401 and Insulin Aspart in Subjects With Type 1 Diabetes.
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2013
At a glance
- Drugs Insulin aspart (Primary) ; Insulin degludec (Primary) ; Insulin degludec/insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 28 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2009 Planned end date changed from 1 Feb 2010 to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 15 Oct 2009 New trial record